                              
                    Identification Potent Inhibitors Trypanosoma brucei
                    Methionyl-tRNA Synthetase High Throughput Orthogonal
                    Screening
                    Laura PedrÃ³-Rosa1,â€ , Frederick S. Buckner2,â€ , Ranae M. Ranade2,â€ , Christina Eberhart1,
                    Franck Madoux1, J. Robert Gillespie2, Cho Yeow Koh3, Steven Brown4, Jacqueline Lohse4,
                    Christophe L. M. Verlinde3, Erkang Fan3, Thomas Bannister1, Louis Scampavia1, Wim G. J.
Author Manuscript




                    Abstract
                         Improved therapies treatment Trypanosoma brucei (T. brucei), etiological agent                          neglected tropical disease human African trypanosomiasis, urgently needed. targeted T.
                         brucei methionyl-tRNA synthetase (MetRS), aminoacyl-tRNA synthase (aaRS), Author Manuscript




                         considered important drug target role protein synthesis, cell survival                          significant differences structure mammalian ortholog. Previous work using RNA
                         interference MetRS demonstrated growth inhibition T. brucei, validating                          attractive target. report development implementation orthogonal high
                         throughput screening assays identify inhibitors T. brucei MetRS.  chemiluminescence
                         assay implemented 1536 plate format used monitor ATP depletion                          aminoacylation reaction. Hit confirmation used counterscreen AMP production
                         assessed using fluorescence polarization technology. addition, miniaturized cell viability
                         assay used triage cytotoxic compounds. Finally, lower throughput assays involving                          parasite growth inhibition human parasite MetRS used analyze compound
                         selectivity efficacy. outcome HTS campaign led discovery nineteen
                         potent selective T. brucei MetRS inhibitors.
Author Manuscript




                    Keywords
                         aminoacyl-tRNA synthetases; high-throughput screening; human African trypanosomiasis;
                         orthogonal screening; Trypanosoma brucei




                    *
                     Address correspondence  Timothy Spicer Scripps Florida 130 Scripps Way #1A1 Jupiter, FL 33458 U.S  spicert@scripps.edu.
                    Â§Current affiliation: Amgen , Thousand Oaks, California.
                     authors equal contributions.
                    PedrÃ³-Rosa et al.                                                                                            Page 2


                       Introduction
Author Manuscript




                                        Aminoacyl-tRNA synthases (aaRS) essential protein synthesis, catalyzing                                         synthesis aminoacyl-tRNAs. catalyzed reaction aaRS usually proceeds                                         steps: recognition specific amino acid ATP form aminoacyl-
                                        adenylate intermediate secondly, recognition associated tRNA transfer                                         aminoacyl group terminal adenosine tRNA. Inhibition step results
                                        disruption protein biosynthesis, attenuating cell growth compromising viability.
                                        aaRS excellent drug targets inhibition, delivering selective cytotoxicity vs.
                                        pathogens. demonstrated development drug mupirocin,                                         selectively inhibits IleRS archaea eubacteria  does inhibit eukaryotic
                                        IleRS.1 aaRSs targeted high throughput screening (HTS) efforts,                                         PheRS MetRS S. aureus.2 HTS program targeting MetRS
                                        protozoan parasite Trypanosoma brucei, including orthogonal counterscreen.
Author Manuscript




                                        T. brucei causative agent neglected tropical disease human African
                                        trypanosomiasis (HAT) threatens ~60 million people sub-Saharan Africa.3                                         left untreated HAT fatal current treatment outcomes unsatisfactory high
                                        toxicity, difficult administration regimes poor efficacy existing drugs.4  new
                                        drugs effective, non-toxic affordable needed. Early studies using RNAi
                                        demonstrated MetRS T. brucei essential parasite survival, making MetRS
                                        inhibition attractive strategy treating HAT.5,6,7 Potent aminoquinolone-based
                                        compounds, like 2-((3-((3,5-dichlorobenzyl)amino)propyl)amino)quinolin-4(1H) (CID
                                        18353708, Figure 2), identified present poor bioavailability.8 Moderately
                                        potent urea-based compounds oxazoloneâ€“dipeptides reported.9,10,11 goal
                                        HTS campaign presented identify selective, potent drug like small
Author Manuscript




                                        molecule T. brucei MetRS inhibitors, ultimate potential novel
                                        therapeutics HAT.

                                        minimize false leads, key aspect effort use orthogonal screens early
                                        program, using different assay technologies, identify novel inhibitors MetRS
                                        catalyzed reaction vitro. reaction monitored measuring residual
                                        ATP AMP MetRS reaction luminescence fluorescence polarization (FP),
                                        respectively. Excellent performance assays 1536 plate format achieved
                                        screen MLSMR collection 364,131 compounds. dozen
                                        tractable compounds sub micromolar potency identified using assays.


                       Materials Methods
Author Manuscript




                       Protein expression purification
                                        length gene T. brucei MetRS (Tb927.10.1500) amplified T. brucei
                                        brucei strain 427, expressed E. coli, purified previously described.8 N-terminal
                                        6 tag retained. human mitochondrial MetRS enzyme expressed,                                         previously reported, plasmid provided Dr. L. Spremulli.12




                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                           Page 3


                       Optimization Miniaturization MetRS inhibition assays
Author Manuscript




                                        assay high-throughput screening required robust, non-radiometric methodology.
                                        ATP depletion assay based chemiluminescence developed initial
                                        screen.13,14 Optimization Kinase-GloÂ® reagent (Promega) initially 96-
                                        format using buffer conditions previously utilized radiometric aminoacylation
                                        assay:8 10 mM MgCl2, 25 mM HEPES-KOH pH 7.9, 50 mM KCl, 2.5 mM dithiothreitol,
                                        0.1 mg/mL bovine serum albumin, 0.2 mM spermine, 10 U/mL pyrophosphatase.                                         achieve separation high controls (wells containing cold L-methionine                                         inhibitors) low controls (wells containing inhibitors) different variables
                                        (incubation time, substrate concentration, enzyme concentration) manipulated
                                        independently conditions held constant. Optimized substrate
                                        concentrations follows: L-methionine 32 ÂµM, bulk E. coli tRNA (Sigma-Aldrich)
                                        200 Âµg/mL, ATP 100 nM. L-methionine range reported Km Author Manuscript




                                        54Â±42 ÂµM15 concentration ATP lower Km reported related
                                        MetRS enzyme E. coli (20 ÂµM).12 necessary use low concentration ATP                                         achieve optimal separation high low controls. substrate
                                        concentrations established, enzyme reaction progress curves (Supplement Figure 1A)
                                        completed determine optimal enzyme concentration incubation time, 50 nM
                                        120 minutes respectively. conditions ATP consumed                                         85  resulted excellent assay reproducibility statistics average -
                                        factor 0.84 (Supplement Figure 1B). DMSO tolerance tested significant
                                        decrease ATP consumption observed 2  DMSO. HTS,
                                        pyrophosphatase decreased 10 0.1 U/mL significant decrease ATP
                                        consumption. assay miniaturized 384 format Scripps Research
                                        Institute (La Jolla, CA) pilot screen 5,120 Maybridge compounds tested 1 ÂµM
Author Manuscript




                                        completed. pilot screen excellent -factors 0.75 â€“ 0.89. Finally, assay
                                        miniaturized 1536 format discussed results section.

                                        stepwise protocol depicted Supplement Table 1. primary luminescence-
                                        based screen, test compounds analyzed singlicate final nominal concentration                                         12 ÂµM using automated Kalypsys/GNF platform (GNF Systems, San Diego, CA)                                         Scripps Research Institute Molecular Screening Center (SRIMSC, Jupiter, FL). cutoff
                                        used qualify active compounds calculated average percent inhibition                                         compounds tested plus times standard deviation.16 confirmation assay                                         orthogonal FP-based counterscreen tested compound triplicate single
                                        concentration (~12 ÂµM). primary assay hit-cutoff applied confirmation assay.
                                        counterscreen employed algorithm determine hit cut  Actives                                         progressed forward determine concentration response curves (CRC) (Table 1). CRC
Author Manuscript




                                        experiments performed  testing compounds triplicate 10-point
                                        serial dilution starting 120 ÂµM. ATP levels measured luminescence using
                                        Kinase-GloÂ® detection reagent (Promega) ViewLux microplate reader (PerkinElmer).
                                        orthogonal assay, AMP levels measured FP using TranscreenerÂ®
                                        AMP2/GMP2 reagent (BellBrook Labs) EnVision microplate reader (PerkinElmer)
                                        using Cy5 FP filter set Cy5 dichroic mirror (excitation = 620 nm, emission = 688



                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                           Page 4


                                        nm). FP read using 50 flashes  details assays Author Manuscript




                                        PubChem website using unique assay identifiers listed Table 1.

                       Cytotoxicity counterscreen
                                        Jurkat cells (clone E6.1, ATCC- TIB-152) cultured suspension growth media
                                        containing RPMI-1640, 10  dialyzed fetal bovine serum, 0.1 mM NEAA, 1 mM sodium
                                        pyruvate, 25 mM HEPES, 5 mM L-glutamine 1Ã— Anti-Anti (Life Technologies,
                                        Carlsbad, CA.) 37Â°C 95  relative humidity 5  CO2. cells                                         added 1536 plates incubated compounds DMSO 18hrs
                                        37Â°C 95  relative humidity 5  CO2, time 5Âµl CellTiter-Glo
                                        (Promega, Madison, WI) added wells. Plates centrifuged incubated                                         10 minutes room temperature. Luminescence measured ViewLux microplate
                                        reader (PerkinElmer, Waltham, MA). Doxorubicin used positive control. Author Manuscript




                                        information, Table 1 PubChem AID 364.

                       Aminoacylation assay (T. brucei human mitochondrial MetRS)
                                        confirm specificity hits HTS, follow screen performed using
                                        aminoacylation assay quantifies incorporation [3H]L-methionine tRNA.8
                                        Reactions performed 96 filter plates Durapore membranes
                                        (MSHVN4B10; Millipore, Billerica, MA) volumes 75 Âµl. reaction buffer 25
                                        mM HEPES-KOH pH 7.9, 10 mM MgCl2, 50 mM KCl, 0.2 mM spermine, 0.1 mg/ml
                                        bovine serum albumin, 2.5 mM dithiothreitol, 0.1 mM ATP, 240 nM [3H]L-methionine (83
                                        Ci/mmol), 2  DMSO, 0.1 U/ml pyrophosphatase (I1643; Sigma-Aldrich, St. Louis,
                                        MO). Recombinant enzyme (10 nM) test compounds (10 ÂµM 1 ÂµM) mixed                                         buffer preincubated 15 min. start reaction, 400 Âµg/ml bulk Escherichia
Author Manuscript




                                        coli tRNA (R4251; Sigma-Aldrich, St. Louis, MO) added plate incubated
                                        shaking room temperature 120 min. reactions stopped                                         addition 100 Âµl cold 10  trichloroacetic acid. reaction components                                         separated tRNA filtration vacuum manifold washed times                                         300 Âµl cold 10  trichloroacetic acid. filter plates dried, 25 Âµl                                         scintillation fluid added, counts plates determined using                                         scintillation plate counter. Samples run triplicate, average activity                                         inhibitors compared control wells inhibitors. Percent inhibition                                         calculated concentrations (10 ÂµM 1 ÂµM).

                                        selectivity counterscreen, hit compounds assayed human
                                        mitochondrial MetRS enzyme using aminoacylation methodology described                                         differences. assay performed reaction buffer containing 50 mM
Author Manuscript




                                        Tris-HCl pH 8.0, 6 mM MgCl2, 2.5 mM KCl, 0.2 mM spermine, 0.2 mg/ml bovine serum
                                        albumin, 2.5 mM dithiothreitol, 2.5 mM ATP, 240 nM [3H]L-methionine (83 Ci/mmol), 2 
                                        DMSO, 0.1 U/ml pyrophosphatase. Recombinant enzyme (13 nM) inhibitors (10
                                        ÂµM 1 ÂµM) mixed buffer pre-incubated 15 min. start reaction,
                                        200 Âµg/ml bulk Escherichia coli tRNA added. plate incubated shaking
                                        room temperature 60 min processed described 



                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                              Page 5


                       T. brucei growth inhibition assay
Author Manuscript




                                        T. brucei (bloodstream form strain 427 K. Stuart, Seattle Biomedical Research
                                        Institute, Seattle, WA) cultured HMI-9 medium17 containing 10  fetal bovine
                                        serum, penicillin, streptomycin 37Â°C 5  CO2. Drug sensitivity T. brucei
                                        strain determined 96 microtiter plates triplicate initial inoculum                                         1Ã—104 trypomastigotes  Compound stock solutions prepared DMSO 20
                                        mM 10 mM added serial dilutions final volume 200 Âµl  Parasite
                                        growth quantified 48 h addition AlamarBlue (Alamar Biosciences,
                                        Sacramento, CA).18 Pentamidine isethionate (Aventis, Dagenham, United Kingdom)                                         included assay positive control. Compounds tested triplicate using 4-
                                        point serial fold dilution starting test concentration 10 ÂµM. Inhibition                                         various concentrations determined EC50 value calculated online
                                        service CDD (www.collaborativedrug.com) using equation sigmoidal
Author Manuscript




                                        dose-response curve.

                       Screening data acquisition, normalization, representation analysis
                                        Raw luminescence data FP values uploaded SRIMSC institutional HTS
                                        database (Symyx Technologies , Santa Clara, CA). Raw luminescence data                                         imported directly FP values calculated using following equation prior                                         upload:




                                        Raw1 defined polarized fluorescence P channel Raw2 defined Author Manuscript




                                        polarized fluorescence S channel.

                                        case, response data normalized using following equation:




                                        High Control represents wells plate containing 1.5 ÂµM control
                                        compound CID 18353708, case cytotoxicity assay, 8 ÂµM doxorubicin,                                         Low Control represents wells treated DMSO 

                                        Data normalized plate basis assay plate underwent quality control
                                        check;  value greater 0.5 required acceptance data.19 CRC data Author Manuscript




                                        analyzed plotting average percent inhibition triplicate results                                         compound concentration. parameter equation describing sigmoidal concentration-
                                        response curve fitted adjustable baseline using Assay Explorer software
                                        (Symyx). Similarly, graphs shown manuscript, CRCs pIC50 values                                         generated Prism (GraphPad Software, San Diego, CA). results                                         screens NIHâ€™s PubChem website (http://pubchem.ncbi.nlm.nih.gov/)
                                        utilizing AID listed Table 1.


                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                          Page 6


                       Cheminformatics
Author Manuscript




                                        Shared scaffolds active compound families confirmation screen CRC
                                        experiments identified using Maximum Common Substructure hierarchical clustering
                                        (ChemAxon LibraryMCS 5.10.2). physical properties  e. molecular mass, topological
                                        polar surface area, chiral atoms, H-bond acceptors/donors, ring count rotatable bonds)                                         compounds tested dose response format calculated (ChemAxon Instant JChem
                                        6.2.2).

                       Chemicals
                                        MLSMR library provided BioFocus DPI (South San Francisco, CA)                                         NIHâ€™s Roadmap Molecular Libraries Initiative. Details regarding compound selection                                         library online http://mli.nih.gov/mli/compound-repository/mlsmr-
                                        compounds/. Briefly, library highly diversified collection small molecules  Author Manuscript




                                        50  molecular weight range 350â€“410 g/mol) comprised synthetic
                                        natural products, commercial academic sources, grouped                                         4 following categories: (1) specialty sets known bioactive compounds drugs
                                        toxins (0.65 ), (2) focused libraries aimed specific target classes (2.85 ), (3) non-
                                        commercial sources (7.4 ) (4) diversity sets covering large area chemical space
                                        (89.1 ).

                                        positive control compound CID18353708 synthesized described 8


                       Results
                       Implementation orthogonal HTS assays
                                        luminescence based assay designed run primary screen identify inhibitors
Author Manuscript




                                        T. brucei MetRS measuring ATP depletion aminoacylation reaction.
                                        Residual ATP measured luciferase catalyzed reaction mono-
                                        oxygenation luciferin substrate (Kinase-GloÂ®) luminescence signal                                         inversely proportional MetRS activity (Figure 1).

                                        reduce cost increase throughput HTS campaign, assay                                         miniaturized implemented 1536 plate format. Optimization assay                                         performed assessing effect critical variables affect aminoacylation
                                        reaction;  e.; MetRS concentration, ATP concentration, DMSO tolerance;                                         Supplement). sets controls, N=24 set, placed assay plate:                                         high control (1.5 ÂµM CID18353708 final), low control containing DMSO (0.9  final)
                                        50  inhibition control containing CID18353708 IC50 concentration (40 nM).
Author Manuscript




                                        controls used (1) ensure T. brucei MetRS activity, (2) normalize data,                                         (3) monitor data quality measuring  S:B. additional controls placed
                                        plate: positive control containing ATP tRNA L-methionine,                                         background control ATP ensure proper compound reagent dispensing. Good
                                        separation controls observed shown plot raw luminescence values
                                        measured primary screen (Figure 2). primary HTS data normalized                                         inhibition compound CID18353708 vs. DMSO wells, used produce 

                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                              Page 7


                                        scatterplot aid visualization activity HTS campaign (Figure 3).
Author Manuscript




                                        Notably positive control compound shown produce sub-micromolar
                                        inhibition T. brucei MetRS.18 final conditions listed Supplement Table 1,
                                        excellent assay performance observed average  factor 0.93 Â± 0.02                                         pIC50=7.62Â±0.05 (IC50=24.20 Â± 2.74 nM) Hill slope 4.41 Â± 0.56                                         CID18353708 (N=11).

                                        orthogonal FP counterscreen implemented help prioritize hit selection                                         removing potential artifacts luminescent detection (quenchers, luciferase
                                        inhibitors, ). assay measures AMP production T. brucei MetRS catalyzed
                                        aminoacylation reaction function proportional MetRS activity. Optimal assay
                                        conditions accord manufacturerâ€™s recommendations (BellBrook Labs,
                                        Madison, WI) subsequent experiments performed using conditions listed                                         Supplement Table 1. miniaturized format,  factor 0.71 Â± 0.02 Author Manuscript




                                        pIC50=7.52Â±0.07 (IC50 = 30.34 Â± 4.81) nM Hill slope 4.34 Â± 0.17                                         CID18353708 (N=3). Inhibition MetRS CID18353708 nearly identical                                         assays, indication good correlation sensitivity assay formats
                                        (Figure 2).

                       T. brucei MetRS inhibition screening campaign results
                                        T. brucei MetRS inhibition screening campaign summarized Table 1. total                                         364,131 distinct samples MLSMR tested primary screen                                         nominal concentration 12 ÂµM.  data indicate robustness step
                                        HTS campaign, did observe high degree variation signal                                         basal ratio (S/B) MetRS luminescence assay. variability batches                                         basal signal levels approaching zero terms raw data relative light units. 
Author Manuscript




                                        small shift raw data, resulted fairly significant shift normalized
                                        S/B. primary screen 1,456 compounds  e. 0.4  total library)                                         identified actives, exhibiting percent inhibition greater nominal hit cutoff                                         5.61  (average background + 3SD).  1,370 available MLSMR                                         testing confirmation counterscreen stages.

                                        order confirm inhibitory activity, eliminate luminescent artifacts, eliminate
                                        broadly cytotoxic compounds, 1,370 samples retested triplicate different
                                        assays: (1) luminescence MetRS ATP depletion assay, (2) fluorescence polarization
                                        AMP production assay, (3) luminescence-based Jurkat cell cytotoxicity assay.                                         161 compounds active cytotoxicity assay eliminated                                         follow  Non-cytotoxic compounds activity ATP depletion AMP
Author Manuscript




                                        formation assays prioritized CRC studies (522 compounds). facilitate compound
                                        selection titration studies, 522 compounds classified 86 clusters based                                         common substructure. compounds CRC studies selected based                                         main criteria: (1) potent compounds cluster selected ensure
                                        chemical diversity (2) compounds exhibited 1:1 Â± 0.6 correlation                                         IC50s target-based assays selected proceed. criteria, 266




                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                              Page 8


                                        compounds selected IC50 titration, 249 compounds available Author Manuscript




                                        MLSMR.

                                        CRCs 249 compounds determined testing triplicate 10 point                                         fold serial dilution format assays. Individual CRCs offered better
                                        insight selectivity compounds inhibition profiles                                         different assays, facilitating triage cytotoxic compounds CID16312830                                         luminescent artifacts CID2810697 (Figure 4 Supplement Table 2).                                         results, compounds, selected follow based criteria: (1) IC50
                                        10 ÂµM luminescence FP assays, (2) overlapping dose response curves                                         luminescence FP assays (maximum percent response 10 percent 
                                        (3) relatively high cytotoxicity index  e.; Jurkat cytotoxicity assay resulting cytotoxic
                                        concentration (CC50) greater 10 times IC50 luminescence assay). total 54
                                        compounds met criteria subjected characterization, including
Author Manuscript




                                        secondary assays structure activity relationship (SAR) studies (Supplement Table 2).

                       Low Throughput Secondary assays
                                        54 confirmed active compounds tested activity aminoacylation assay vs.
                                        T. brucei cells grown culture. data shown Supplement Table 2 compounds
                                        ranked pIC50 luminescence dose-response assay 1536 format.
                                        Nineteen compounds sub-micromolar IC50 values ATP depletion assay
                                        potent compound (CID 24793614) having IC50 44 nM. Results                                         orthogonal FP assay showed strong correlation luminescent assay                                         R2=0.895. activity compounds determined low-throughput
                                        aminoacylation assay measures incorporation [3H]L-methionine tRNA.                                         compounds demonstrated enzyme inhibition secondary assay single
Author Manuscript




                                        compound (CID 4656759) having somewhat discordant result (28  inhibition 10 M
                                        compared IC50 value 2.2 M ATP depletion assay).

                                        assess parasite vs. human selectivity, 54 confirmed active compounds assayed
                                        human mitochondrial MetRS using aminoacylation methodology.                                         compounds (81 ) showed weak inhibition human mitochondrial MetRS
                                         e.; <20  10 M). compounds >30  inhibition human enzyme,
                                        indicating screen successful identifying numerous active compounds                                         specific trypanosome mammalian MetRS. compound (CID
                                        46902334) moderately potent human mitochondrial MetRS (80.3 
                                        inhibition 10 M, 14.3  inhibition 1 M). noted earlier, selection criteria
                                        compound progression low cytotoxicity; CC50 Jurkat cells >10 M.
Author Manuscript




                                        Supplement Table 2, shows Jurkat CC50 data; majority compounds (66.7 )                                         inhibitory activity highest dilution (83.3 M) single compound (CID
                                        3718852) CC50 <20 M.

                                        Finally, 54 compounds tested growth inhibition activity (EC50) T. brucei
                                        cultures. compounds (22.2 ) showed degree inhibition 10 M.                                         potent compounds apparent EC50s 2 M range. compounds screening
                                        hits penetrate cells  important criterion drug discovery efforts.


                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                             Page 9


                       Discussion
Author Manuscript




                                        Orthogonal screens successfully developed implemented identify potent small
                                        molecule inhibitors T. brucei MetRS, using ATP AMP levels reporters MetRS
                                        activity luminescence fluorescence polarization detection methods, respectively.
                                        assays technologies demonstrated robust performance Kalypsys GNF ÂµHTS
                                        platform. noted, batch batch variability observed overall signal basal
                                        ratio (S/B) primary screen. finding little concern given   data
                                        normalized plate plate basis, (ii) relative shift raw data minor                                         resulted substantial shifts S/B (iii) pharmacological control behaved 
                                        giving expected IC50. maintained  values > 0.8 average throughput                                         approximately 15,000 compounds hour HTS campaign (Supplement
                                        Figure 4). use substrate (ATP) depletion assay primary screen necessitated
                                        high fractional conversion ~85  substrate robust signal (Supplement Figure
Author Manuscript




                                        1A). high fractional conversion substrate associated lower sensitivity                                         identifying inhibitors.20 Notably, enzyme ATP concentration nearly
                                         50 nM 100nM respectively, assay run conditions enabling
                                        limited turnover  minimize sensitivity slow binding inhibitors. Assay
                                        operating conditions HTS predicated working substrate concentrations
                                        significantly lower Km; condition prevents identification ATP
                                        uncompetitive inhibitors.  given large number confirmed hits (1,270)
                                        identified initial high-throughput screen, felt assay methodology                                         sufficient provide ample numbers hits forward downstream
                                        analysis.

                                        Use orthogonal FP-based counterscreen eliminate detection format-specific hits
Author Manuscript




                                         CID2810697) eliminated nuisance compounds early process allowed                                         high confirmation rate subsequent secondary assays. addition, cytotoxic compounds
                                         e.; CID16312830) eliminated advancement based results Jurkat
                                        assay. battery complementary assays proved effective way quickly
                                        identify inhibitors aaRS. Initial SAR analysis CID2973195, indole oxalamide
                                        shown Figure 4C, demonstrated excellent  boxâ€? potency primary FP
                                        assays relatively cytotoxicity; pIC50 values respective order  6.77, 6.53, <4.08
                                        (IC50 values 171 nM, 292 nM, >83 ÂµM respectively).

                                        Virtually compounds selected low-throughput screening (52/54) confirmed                                         active T. brucei aminoacylation assay. methodology measures MetRS
                                        enzyme reaction quantifying incorporation [3H]L-methionine tRNA. Author Manuscript




                                        confirmatory results reassuring showed HTS assay cascade used                                         effective.

                                        human mitochondrial MetRS potential target hits, tested                                         set compounds human mitochondrial enzyme. noted human
                                        cells contain cytoplasmic MetRS, homology T. brucei MetRS                                         active site relatively low (46  identical residues), homology human
                                        mitochondrial MetRS active site T. brucei MetRS higher (79  identical


                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                                        Page 10


                                        residues). human selectivity screen showed 81  percent compounds â‰¤20 
Author Manuscript




                                        inhibition human mitochondrial MetRS, meaning developed drugs, relatively
                                        compounds likely cause host toxicity, inhibiting human enzyme HAT
                                        patients. selectivity hit set likely enhanced earlier implementation                                         Jurkat cytotoxicity screen. concluded differences human
                                        mitochondrial trypanosomal MetRS (21  amino acid sequence difference ATP-
                                        methionine binding sites) sufficient make selective inhibition small molecules
                                        possible. Structural studies compounds bound T. brucei MetRS aid
                                        understanding guide enhancements potency selectivity hit
                                        compounds.

                                        Finally, 12 54 HTS hit compounds (22 ) inhibited growth T. brucei grown                                         culture. assumed case growth inhibition observed inhibition                                         MetRS target, work necessary confirm hypothesis. Author Manuscript




                                        shown previous work aminoquinolone MetRS inhibitors fact block protein
                                        synthesis cultured T. brucei cells.10 likely 42 compounds inactive vs.
                                        cultured T. brucei poor membrane permeability reach target. 
                                        weaker MetRS inhibitors sufficiently bind target affect growth                                         concentrations tested, enter cells.

                                        screening approach used campaign exhibited great robustness ability
                                        rapidly identify triage potent, non-cytotoxic compounds. combination                                         secondary assays, promising selective compounds  pIC50 values high 7.36
                                        IC50 low 44 nM) identified pursued future studies                                         development novel potent molecular probes, ultimately leading drug                                         treat HAT. orthogonal screening approach, using automated platform, proven
Author Manuscript




                                        excellent tactic screen large compound libraries certainly extended                                         aaRSs.


                       Supplementary Material
                                        Refer Web version PubMed Central supplementary material.


                       Acknowledgements
                                        work supported National Institutes Healthâ€™s Roadmap Initiative grants U54MH084512
                                        (LPR, CE, FM, SB, JL, TB, LS, TS, PH), PO1AI067921 [Medical Structural Genomics Pathogenic Protozoa
                                        (MSGPP)] RO1AI084004 WGJH, RO1 AI097177 FB EF). thank Pierre Baillargeon Lina
                                        DeLuca (Lead Identification, Scripps Florida) compound management MSGPP workers                                         contributions early stages project.
Author Manuscript




                       References
                                        1. Nakama T, Nureki O, Yokoyama S. Structural basis recognition isoleucyl-adenylate                                            antibiotic, mupirocin, isoleucyl-tRNA synthetase. Journal biological chemistry. 2001;
                                           276(50):47387â€“47393. [PubMed: 11584022]
                                        2. Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs bad bugs: confronting challenges                                            antibacterial discovery. Nat Rev Drug Discov. 2007; 6(1):29â€“40. [PubMed: 17159923]




                                            J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                                  Page 11


                                        3. Hotez PJ, Molyneux DH, Fenwick  et al. Control neglected tropical diseases. N Engl J Med.
                                           2007; 357(10):1018â€“1027. [PubMed: 17804846]
Author Manuscript




                                        4. Brun R, Blum J, Chappuis F, et al. Human African trypanosomiasis. Lancet. 2010; 375(9709):148â€“
                                           159. [PubMed: 19833383]
                                        5. Sheppard K, Yuan J, Hohn MJ, et al. amino acid  tRNA-dependent amino acid
                                           biosynthesis. Nucleic Acids Res. 2008; 36(6):1813â€“1825. [PubMed: 18252769]
                                        6. Hurdle JG, O'Neill AJ, Chopra  Prospects aminoacyl-tRNA synthetase inhibitors new
                                           antimicrobial agents. Antimicrobial agents chemotherapy. 2005; 49(12):4821â€“4833. [PubMed:
                                           16304142]
                                        7. Raczniak G, Ibba M, Soll D. Genomics-based identification targets pathogenic bacteria                                            potential therapeutic diagnostic use. Toxicology. 2001; 160(1â€“3):181â€“189. [PubMed:
                                           11246138]
                                        8. Shibata S, Gillespie JR, Kelley  et al. Selective inhibitors methionyl-tRNA synthetase                                            potent activity Trypanosoma brucei Infection Mice. Antimicrobial agents                                            chemotherapy. 2011; 55(5):1982â€“1989. [PubMed: 21282428]
                                        9. Koh CY, Kim JE, Wetzel AB, et al. Structures Trypanosoma brucei Methionyl-tRNA Synthetase
Author Manuscript




                                           Urea-Based Inhibitors Provide Guidance Drug Design Sleeping Sickness. PLoS
                                           neglected tropical diseases. 2014; 8(4):e2775. [PubMed: 24743796]
                                        10. Shibata S, Gillespie JR, Ranade RM, et al. Urea-based inhibitors Trypanosoma brucei
                                            methionyl-tRNA synthetase: selectivity vivo characterization. J Med Chem. 2012; 55(14):
                                            6342â€“6351. [PubMed: 22720744]
                                        11. Tandon M, Coffen DL, Gallant P, et al. Potent selective inhibitors bacterial methionyl tRNA
                                            synthetase derived oxazolone-dipeptide scaffold. Bioorganic & medicinal chemistry
                                            letters. 2004; 14(8):1909â€“1911. [PubMed: 15050625]
                                        12. Spencer AC, Heck  Takeuchi N, et al. Characterization human mitochondrial methionyl-
                                            tRNA synthetase. Biochemistry. 2004; 43(30):9743â€“9754. [PubMed: 15274629]
                                        13. Godeau JM, Charlier J. Adenosine triphosphate consumption bacterial arginyl-transfer
                                            ribonucleic acid synthetases. Biochemical journal. 1979; 179(2):407â€“412. [PubMed: 384995]
                                        14. Wu Y, Yu K, Xu B, et al. Potent selective inhibitors Staphylococcus epidermidis
                                            tryptophanyl-tRNA synthetase. Journal antimicrobial chemotherapy. 2007; 60(3):502â€“509.
Author Manuscript




                                            [PubMed: 17606484]
                                        15. Cestari  Kalidas S, Monnerat S, et al. multiple aminoacyl-tRNA synthetase complex                                             enhances tRNA-aminoacylation African trypanosomes. Molecular cellular biology. 2013;
                                            33(24):4872â€“4888. [PubMed: 24126051]
                                        16. Madoux F, Simanski S, Chase P, et al. ultra-high throughput cell-based screen wee1
                                            degradation inhibitors. Journal biomolecular screening. 2010; 15(8):907â€“917. [PubMed:
                                            20660794]
                                        17. Hirumi H, Hirumi K. Continuous cultivation Trypanosoma brucei blood stream forms                                             medium containing low concentration serum protein feeder cell layers. Journal                                             parasitology. 1989; 75(6):985â€“989. [PubMed: 2614608]
                                        18. Koh CY, Kim JE, Shibata S, et al. Distinct states methionyl-tRNA synthetase indicate inhibitor
                                            binding conformational selection. Structure. 2012; 20(10):1681â€“1691. [PubMed: 22902861]
                                        19. Zhang JH, Chung TD, Oldenburg KR. Simple Statistical Parameter Use Evaluation                                             Validation High Throughput Screening Assays. Journal biomolecular screening. 1999; 4(2):
                                            67â€“73. [PubMed: 10838414]
Author Manuscript




                                        20. Wu G, Yuan Y, Hodge CN. Determining appropriate substrate conversion enzymatic assays                                             high-throughput screening. Journal biomolecular screening. 2003; 8(6):694â€“700. [PubMed:
                                            14711395]




                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                       Page 12
Author Manuscript
Author Manuscript




                                        Figure 1.
                                        T. brucei MetRS catalyzed reaction. primary screen assay focuses luminescence
                                        signal generated luciferase catalyzed reaction using residual ATP. orthogonal
                                        counterscreen focuses fluorescence polarization signal generated                                         displacement labeled AMP molecule selective antibody AMP generated
                                        T. brucei MetRS catalyzed reaction.
Author Manuscript
Author Manuscript




                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                       Page 13
Author Manuscript
Author Manuscript




                                        Figure 2. Assay controls
                                         Compound CID 18353708 used assay pharmacological control. B) Average
                                        raw luminescence units controls used primary screen assess assay quality. 100 
Author Manuscript




                                        inhibition control wells contain compound CID 18353708 1.5ÂµM. 50  inhibition wells
                                        contain CID 18353708 concentration corresponding IC50 0  inhibition control
                                        wells contain assay components DMSO, ATP positive control correspond wells                                         containing L-methionine, background control refers wells containing ATP. C)
                                        CRC results reference control CID 18353708 orthogonal assays. (â—?) Luminescence
                                        curve (â—‹) fluorescence polarization assay curve. Reference compound tested 20-
                                        point, 2:1 serial dilution starting 15ÂµM.
Author Manuscript




                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                      Page 14
Author Manuscript
Author Manuscript




                                        Figure 3. Primary screen scatter plot
                                        (âˆ†) Represent low control wells containing DMSO  (â—?) represent data wells containing
                                        compounds (â– ) represent high control wells containing compound CID18353708. Author Manuscript




                                        dashed line represents hit cut  Compounds inhibition line                                         considered primary actives hits.
Author Manuscript




                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                    PedrÃ³-Rosa et al.                                                                                         Page 15
Author Manuscript
Author Manuscript




                                        Figure 4. Compound dose response curves
                                        (â—?) Luminescence curve (â—‹) fluorescence polarization assay curve (â–²) cytotoxicity assay
                                        curve.  Compound CID 2810697 flagged luminescent artifact inactivity                                         fluorescence polarization assay. B) Compound CID 16312830 flagged cytotoxic
                                        compound activity Jurkat cytotoxicity assay. C) Compound CID 2973195
                                        identified potent hit high potency T. brucei MetRS assay modes
                                        low cytotoxic effect Jurkat cells.
Author Manuscript
Author Manuscript




                                           J Biomol Screen. Author manuscript; available PMC 2015 March 30.
                                                                      Author Manuscript                               Author Manuscript                                   Author Manuscript                                    Author Manuscript


                                                                                                                                                                        Table 1

                                                                            Ultra-High-Throughput Screening Campaign Summary Results

                                                                                                                                                                                                                        Assay Statistics

                                                                                Step   Screen type      Target      Number        Number            Selection       Number        *PubChem                        S/B
                                                                                                                                                                                                                                                   PedrÃ³-Rosa et al.




                                                                                                                    compounds        replicates/          Criteria          selected          AID
                                                                                                                      tested       concentrations                         compounds
                                                                                                                                                                             (Hits)
                                                                                 1       Primary        MetRS         364,131            1/1             inh> 5.61           1,456          624268       0.90 Â± 0.03    16.33 Â± 13.13
                                                                                2a     Confirmation     MetRS          1,370             3/1             inh> 5.61      1,270 (522, 266)    624412       0.92 Â± 0.02     7.10 Â± 0.20
                                                                                2b     Cytotoxicity   Cell growth      1,370             3/1          inh> 14.97  161       624413         0.83